Reviva Pharmaceuticals Holdings, Inc. Earnings Per Share, Basic and Diluted
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Earnings Per Share, Basic and Diluted of -$0.58 per share for the 11-month period ending 2021-12-13, per its 10-K filed 2022-03-15.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-03-15
- Reviva Pharmaceuticals Holdings, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.12.
- Reviva Pharmaceuticals Holdings, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.12.
- Reviva Pharmaceuticals Holdings, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.10.
- Reviva Pharmaceuticals Holdings, Inc. earnings per share, basic and diluted for the quarter ending 2020-11-30 was -$0.13.
- Reviva Pharmaceuticals Holdings, Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.24.
- Reviva Pharmaceuticals Holdings, Inc. earnings per share, basic and diluted for fiscal 2020 was -$0.21.
- Reviva Pharmaceuticals Holdings, Inc. earnings per share, basic and diluted for fiscal 2019 was -$0.31.
| Period end | Earnings Per Share, Basic and Diluted 2 month | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 5 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 8 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 11 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|---|---|
| 2021-12-13 | -$0.58 10-K · filed 2022-03-15 | |||||||
| 2021-09-30 | -$0.12 10-Q · filed 2021-11-15 | -$0.36 10-Q · filed 2021-11-15 | ||||||
| 2021-06-30 | -$0.12 10-Q · filed 2021-08-16 | -$0.23 10-Q · filed 2021-08-16 | ||||||
| 2021-03-31 | -$0.10 10-Q · filed 2021-05-17 | |||||||
| 2020-12-31 | -$1.24 10-K · filed 2022-03-15 | |||||||
| 2020-11-30 | -$0.13 10-Q · filed 2021-01-14 | -$0.40 10-Q · filed 2021-01-14 | ||||||
| 2020-09-30 | -$0.24 10-Q · filed 2021-11-15 | -$0.82 10-Q · filed 2021-11-15 | ||||||
| 2020-08-31 | -$0.19 10-Q · filed 2020-10-14 | -$0.28 10-Q · filed 2020-10-14 | ||||||
| 2020-06-30 | -$0.31 10-Q · filed 2021-08-16 | -$0.58 10-Q · filed 2021-08-16 | ||||||
| 2020-05-31 | -$0.09 10-Q · filed 2020-07-07 | |||||||
| 2020-03-31 | -$0.27 10-Q · filed 2021-05-17 | |||||||
| 2020-02-29 | -$0.13 derived: net income ÷ weighted average shares · filed 2020-05-04 | -$0.18 derived: net income ÷ weighted average shares · filed 2021-01-14 | -$0.20 derived: net income ÷ weighted average shares · filed 2021-01-14 | -$0.21 10-K · filed 2020-05-04 | ||||
| 2019-12-31 | -$0.31 10-K/A · filed 2021-05-07 | |||||||
| 2019-11-30 | -$0.05 10-Q · filed 2021-01-14 | -$0.07 derived: net income ÷ weighted average shares · filed 2021-01-14 | -$0.08 10-Q · filed 2021-01-14 | |||||
| 2019-08-31 | -$0.02 10-Q · filed 2020-10-14 | -$0.03 10-Q · filed 2020-10-14 | ||||||
| 2019-05-31 | -$0.01 10-Q · filed 2020-07-07 | |||||||
| 2019-02-28 | -$0.04 10-K · filed 2020-05-04 | |||||||
| 2018-11-30 | -$0.02 10-Q · filed 2020-01-10 | -$0.02 derived: net income ÷ weighted average shares · filed 2020-01-10 | -$0.03 10-Q · filed 2020-01-10 | |||||
| 2018-08-31 | $0.00 10-Q · filed 2019-10-08 | -$0.01 10-Q · filed 2019-10-08 | ||||||
| 2018-05-31 | -$0.01 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |